Kornimate/medical-research-clean huggingface dataset:
phase iii acute coronary syndrome

Conditions: Acute Coronary Syndrome

Summary: the purpose of this study is to determine if apixaban is superior to placebo for preventing cardiovascular death, non-fatal myocardial infarction, or ischemic stroke in subjects with a recent acute coronary syndrome


Eligibility criteria:
inclusion criteria: * acute coronary syndrome (acs) * clinically stable * receiving standard of care for acs exclusion criteria: * severe hypertension * active bleeding or high risk for major bleeding * hemoglobin \< 9 g/dl

Keywords: nos
time to thrombocytic inhibition after supine and upright ingestion of efient

Conditions: Heart Disease; Ischemic Heart Disease; ST-elevation Myocardial Infarction

Summary: the purpose of the study is to clarify wether body posture during ingestion of 60mg efient, a thrombocytic inhibitor, has influence on the time to thrombocytic inhibition. the study aims to mimic the treatment danish patients receive when admitted to the hospital with a st-elevation myocardial infarction since these patients are refereed to acute percutaneous coronary intervention (pci) necessitating fast and efficient thrombocytic inhibition. current guidelines recommend the administration of efient right before the pci procedure, while the patient is lying down, either in the ambulance or in the operating room. we, the investigators, believe that this is suboptimal for the patient, since any sort of prolonged inhibition time will possibly worsen the patients prognosis and make the patient more prone to later clotting issues. our hypothesis is that by making the patients ingest the tablets in a 90 degrees upright position and making them sit up for 2 minutes after ingestion, the effect of the pills will commence faster than if taken in a supine position. this will possibly lead to faster inhibition of the thrombocytes, which we believe will lead to a lower incidence of clotting issues during and after the procedure.

the study will be divided into two sessions: first session will be the control arm- ingestion of efient in supine position. 14 days later, the same test-persons will be doing the intervention- ingestion of efient sitting upright for 2 minutes. besides this, the second session will be exactly the same as the control arm.

Eligibility criteria:
inclusion criteria: * 20-30 years of age * healthy * male * ability to give informed consent * non-smoker exclusion criteria: * known with reflux or dysphagia * ingestion of medicine, beside paracetamol \<14 prior to the trial * hematological diseases * diabetes * known kidney disease * known liver disease * recent trauma * scheduled operation within 7 days after the trial * former apoplexia * known gastro-intestinal disease * weight \<60 kg

Keywords: pci stemi interventions heart disease thrombocytic inhibition cross-over study percutaneous coronary intervention
phase 1 study of acr-2316 in specific advanced solid tumors

Conditions: Specific Advanced Solid Tumors

Summary: this is a first in-human, open-label phase 1 study to assess the safety of acr-2316 for the treatment of subjects with specific, histologically confirmed, locally advanced, recurrent or metastatic solid tumors.

the phase 1 monotherapy clinical trial for acr-2316 is designed to assess the safety and tolerability of acr-2316. additional objectives include the determination of the maximal tolerated dose and recommended phase 2 monotherapy dose, characterization of the pharmacokinetic profile, and preliminary evaluation of anti-tumor activity.

Eligibility criteria:
inclusion criteria: 1. signed written informed consent. 2. histologically or cytologically proven metastatic, recurrent or locally advanced selected solid tumors. 3. eastern cooperative oncology group (ecog) performance status of 0 to 1 at trial entry and an estimated life expectancy of at least 3 months. 4. disease must be measurable with at least 1 unidimensional measurable lesion by recist v1.1. 5. adequate organ functions. 6. must have progressed after prior line of treatment. exclusion criteria (all participants): 1. participants with known symptomatic brain metastases. 2. participant had systemic therapy or radiation therapy within 2 weeks prior to the first dose of study drug. 3. women who are pregnant or lactating.

Keywords: acr-2316 wee1 pkmyt1 locally advanced, recurrent or metastatic solid tumors
effect of yoghurts enriched with xxs (mixture of natural polyphenolic compounds and plant extracts) on the evolution of weight in overweight subjects

Conditions: Obesity; Overweight

Summary: overweight and obesity are public health problems worldwide. even though heredity may be one of the causes the diseases, the vast majority of cases is rather linked to a sedentary lifestyle associated or not with a low-variety, high-calorie diet. many diets and slimming methods propose low-calorie meals or physical exercise, and the consequences of these are sometimes negative with advancing age (muscle wasting). certain studies have shown the efficacy of foods with antioxidant properties on the reduction of blood pressure, low density lipoprotein (ldl)-cholesterol and weight or on the distribution of fat mass-lean mass. the investigators put forward the hypothesis that the daily consumption of two yoghurts containing xxs, a mixture of natural polyphenolic compounds -rich in quercetin- from plant extracts, could lead to weight loss, a better fat mass-lean mass distribution and an improvement in markers of oxidative stress in overweight persons aged 50 to 65 years.


Eligibility criteria:
inclusion criteria: * men or women aged between 50 and 65 years; * who have provided written consent; * and are covered by national health insurance; * with a stable weight for 6 months and no intention to begin a diet in the coming three months; * with a body mass index (bmi) between 25 and 29.9 kg/m2 and a waist circumference \> 80 cm in women and \> 94cm in men (thresholds of the international diabetes federation, idf); * who consume dairy products such as yoghurts; * and do not have more than two of the following risk factors of metabolic syndrome: known history of hypertension (\>130/85mmhg), hypocholesterolemia high density lipoprotein hdl (\ 1.5 g/l), diabetes (\> 1.1 g/l); * presenting c reactive protein (crp) \< 6mg/l. exclusion criteria: * adults under guardianship * persons following a prescribed of self-prescribed diet; * whose behaviour may interfere with the consumption of the active dairy product (more than 4h of physical activity a week, smoking more than 10 cigarettes a day, more than 2 glasses of alcohol a day, consuming more than one bar of dark chocolate a day, 10 cups of coffee/day, 5 large cups of tea/day, supplementation with vitamins (a, c, e...), oligoelements or minerals (se, zn, ca...), enriched dairy products or any supplements containing dietary foods for specialized medical purposes (adfms) .
innate immunity stimulation via tlr9 in early ad

Conditions: Mild Cognitive Impairment; Alzheimer Dementia

Summary: this single-center, double-blind, placebo-controlled study will recruit in total 39 participants with either mild cognitive impairment due to alzheimer's disease (mci) or mild alzheimer's disease dementia (mild ad). there will be 3 dose levels. an initial cohort of 13 subjects will be randomized to a dose level 1 (0.1 mg/kg vs. placebo) lasting 8 weeks. an additional 13 subjects will be recruited and randomized into dose level 2 (0.25 mg/kg vs. placebo) for 8 weeks and 13 subjects for the last dose level 3 (0.5 mg/kg vs. placebo) for 8 weeks. the primary objective will be to assess safety and tolerability of cpg 1018.


Eligibility criteria:
inclusion criteria: 1. 65-85 years of age 2. mci due to ad or mild ad dementia per nia-aa specified criteria published in 2018 3. montreal cognitive assessment (moca) score ≥17 and; 4. positive florbetaben pet amyloid scan, or other positive pet amyloid scan performed within one year of study enrollment 5. must be able to provide consent or assent (if applicable). 6. must be willing and able to participate in all study related procedures. 7. must have a reliable study partner to provide information on the subject's cognitive and functional status. study partner must have sufficient contact with the subject, as determined by the pi, and be available to accompany the subject to clinic visits or by phone. exclusion criteria: 1. history of psychiatric illness (e.g. hallucinations, major depression, suicidal ideation or delusions) that could interfere with completion of study related procedures as determined by pi 2. history of autoimmune disorders or antibody-mediated disease, severe asthma, or other serious infection or systemic illness, as determined by pi 3. use of corticosteroids or immunosuppressive drugs within 30 days of study entry 4. history of splenectomy 5. renal impairment 6. use of chloroquine within 8 weeks of study entry 7. inability to undergo mri imaging 8. history of tia, stroke or seizures within 12 months of screening 9. any neurological condition other than ad that could contribute to cognitive impairment (including related to possible "long covid") as determined by pi 10. participation in any other current ad investigational interventional trial 11. current use of an anti-coagulant 12. current use of drugs that are major substrates of cytochrome p450 (cyp) enzyme 1a2 13. recent exposure to covid-19 infection within 14 days or recent onset of symptoms within 14 days that may be related to covid-19 infection
effect of dapagliflozin on vt in patients with heart failure.

Conditions: Heart Failure

Summary: this project plans to design a randomized controlled clinical trial to evaluate the effect of dapagliflozin on ventricular arrhythmia in the participants with heart failure with reduced ejection fraction after icd implantation by collecting and analyzing the data of ecg, cardiac ultrasound and icd programming. this project will explore the anti-ventricular arrhythmia effect of dapagliflozin in hfref patients.

this is a single-center, randomized, controlled, double-blind study in chinese heart failure participants with icd implantation. this trial aims to investigate the effect of dapagliflozin on ventricular arrhythmias in participants with hfref. this trial includes a screening period, a treatment period and a follow-up period. total duration of each subject's participation in the trial is approximately 1 year. during the screening period, 120 participants with hfref with icd implanted in the investigator's department were recruited. the participants should sign the informed consent and be randomly divided into 2 groups. all participants will receive the best anti-heart failure treatment for 6 months before enrollment, including acei/arb/arni, β-blockers, spironolactone, diuretics, and digitalis. one group was randomized to receive dapagliflozin (10 mg qd) and another group received place. participants were then enrolled in a 1-year clinical trial and investigators will record the participants' qt interval, qtc interval, frequency and mode of icd electrical therapy, cardiac function, symptoms, signs and other indicators before and after treatment to evaluate the occurrence of ventricular arrhythmia.

Eligibility criteria:
inclusion criteria: patients received icd therapy with hfref, including: ischemic cardiomyopathy, non-ischemic cardiomyopathy, lvef ≤35% and optimized anti-hf therapy for at least 6 months. exclusion criteria: 1. type 1 diabetes or a history of repeated diabetic ketoacidosis. 2. those who strictly restrict carbohydrate intake. 3. genital infection. 4. low blood pressure. 5. sglt2i allergy. 6. severe renal impairment or end-stage renal disease (egfr\<30ml/(min•1.73m\^2)) or dialysis. 7. the water-electrolyte and acid-base balance disorders have not been corrected. 8. bladder cancer. 9. those taking other antiarrhythmic drugs except beta-blockers. 10. other diseases cause the patient's life expectancy to be less than 1 year.

Keywords: heart failure dapagliflozin ventricular arrhythmia clinical randomized controlled trial
insufflation of carbon dioxide during cardiac surgery as prevention neurologic complications

Conditions: Air Embolism; Neurological Damage

Summary: effect of intraoperative insufflation of carbon dioxide on the neurologic complications in the early postoperative period after open cardiac surgery.

arterial air embolism in cardiac surgery is not a rare complication, leading to neurological damage in the early postoperative period of 3-5%. insufflation of carbon dioxide (co2) into the operative field to prevent cerebral or myocardial damage by air embolism is reported since 1967 in open heart surgery (selman mw et al. 1967). carbon dioxide fills the thoracic cavity by gravity and replaces air if adequately insufflated. because solubility of co2 is better than that of air, occlusion or flow disruption in arteries of the brain or the heart is thought to be diminished. despite carefully performed deairing procedures as puncturing of the ascending aorta and cardiac massage, transcranial doppler studies revealed large amounts of emboli during the first ejections of the beating heart (van der linden j et al. 1991). in patiens with minimally invasive approach and redo valve surgery, deairing of the cardiac chambers has become more difficult. although the use of carbon dioxide when filling in the surgical field, as the prevention of air embolism reduces the number of intracardiac emboli according to transesophageal echocardiography there is no evidence of a sustained reduction in cerebrovascular events (g. salvatore al. 2009).

Eligibility criteria:
inclusion criteria: * able to sign informed consent and release of medical information forms * age 18 - 70 years * patients scheduled on cardiac surgery with opening cavities exclusion criteria: * history of stroke and tia * significant carotid artery stenosis * presence of initial severe encephalopathy * re-clamping of the aorta * emergency surgery

Keywords: carbon dioxide postoperative cerebrovascular complications air embolism
dose-response-study with a recombinant cocktail of phleum (rphleum) allergens

Conditions: Type I-Allergy

Summary: dose-response trial with a cocktail of recombinant major allergens of timothy grass pollen (phleum pratense)


Eligibility criteria:
inclusion criteria: * main symptoms of allergic rhinitis/rhinoconjunctivitis with or without controlled asthma against grass pollen allergens * positive spt * positive east * positive specific provocation test exclusion criteria: * serious chronic diseases * other perennial allergies
family healthy living early intervention program

Conditions: Obesity; Health Behavior; Child Behavior; Child Obesity; Nutrition Disorders; Body Weight

Summary: the childhood healthy weights early intervention program (eip) is a family-based pilot program that will promote healthy lifestyle practices for families whose children are off the healthy weight trajectory (e.g., bmi ≥ 85th percentile for age and sex) that do not need the intensive services of medically supervised programs. it is a lifestyle behaviour approach for promoting healthy weights in children. the eip program consists of 10 weekly intervention sessions (1.5 hours per session) followed by 4 maintenance sessions and is age specific (age 8-12). during the intervention, participants will also have access to digital educational content that is supplementary to what is provided during the individual sessions. the program will be integrated and aligned with existing bc-specific childhood healthy weights programs (e.g. the healthlinkbc eating and activity program for kids). the eip pilot will run from october-december 2018 with 8 child programs (age 8-12). participants who do not qualify for this program (e.g., bmi ≤ 85th percentile for age and sex) will be offered a 10 week online program which is similar in educational content as the eip program.


Eligibility criteria:
inclusion criteria: * child with bmi ≥ 85th percentile for age and sex * child is accompanied by a parent or legal guardian * at least one member of the family have to be able to speak and read english * family agrees to attend group meetings over 10 weeks exclusion criteria: * child unavailable to attend group weekly sessions * parent or guardian unavailable to attend group weekly sessions * participating child or parent, according to parent report, has medical condition contraindicating mild energy restriction or moderate physical activity, and medical clearance was not obtained

Keywords: family-based community-based healthy weights
clinical characteristics, anti-hyperglycaemic treatment pattern and target attainment of type 2 diabetes mellitus patients in older population with or without albuminuria in china

Conditions: Type 2 Diabetes Mellitus

Summary: this is a multi-centre, cross-sectional, non-interventional study assessing blood glucose target attainment, anti-hyperglycaemic treatment pattern and the clinical characteristics in older outpatients with type 2 diabetes mellitus (t2dm) in hospitals of china. this study is designed to collect information of older t2dm patients in a real life setting


Eligibility criteria:
inclusion criteria * patient should fully know and understand the content of consent form, and the patient is willing and able to sign an informed consent form * outpatient with confirmed t2dm (according to the american diabetes association criteria 2015 \[r16-1532\]) * age≥60 years exclusion criteria * patients with type 1 diabetes mellitus or secondary dm * patients who are participating in any other clinical study, including any questionnaire-based study, any interventional study (including diet/counselling based intervention), or any clinical study in which any medications (including chinese herbal medications) are administered
tailored response to psychiatric comorbidity to improve hiv care engagement in the united states

Conditions: HIV/AIDS; Depression; Anxiety; Post-traumatic Stress Disorder; Substance Use Disorders

Summary: this pilot randomized clinical trial will randomize 60 participants 1:1 to either enhanced usual care or to adapted common elements treatment approach (ceta), a counseling intervention for hiv care engagement plus depression, anxiety, ptsd, and/or substance use.

patient participants in this study will be randomized 1:1 to either enhanced usual care or the adapted ceta intervention. enhanced usual care will include provision of feedback about psychiatric diagnoses to the hiv provider and the clinic's behavioral health team for follow-up according to the clinic's standard care. participants randomized to the adapted ceta arm will initiate ceta with the trained counselor. the number of ceta sessions will depend on the patient's presentation but will range from 7-13 weekly in-person 1-hour sessions.before randomization, enrolled participants will complete a baseline assessment including sociodemographic information; self-reported health; standardized assessments of depressive, anxiety, and post-traumatic stress symptoms and substance use; and key related structural and psychosocial factors including housing stability,intimate partner violence (ipv), other violence in the home, coping, social support, and experiences of stigma related to mental health. participants in the enhanced contact arm will complete a follow-up research assessment at 3 months post baseline.participants in the adapted ceta arm will complete this assessment after the final ceta session,also expected to be at approximately 3 months post-baseline. all participants will complete a final research assessment at 9 months post-baseline (approximately 6 months post-treatment exit for those in the adapted ceta arm). these follow-up assessments will assess the same domains as the baseline assessment.

Eligibility criteria:
inclusion criteria: 1. age \>= 18 years. 2. patient receiving hiv care at university of alabama at birmingham (uab) 1917 clinic. 3. elevated symptoms of depression, anxiety, post-traumatic stress, or substance use disorder: at least one of the following: 1. patient health questionnaire-9 score \>= 10; 2. generalized anxiety disorder 7-item scale score \>= 10; 3. post-traumatic stress symptoms checklist for diagnostic and statistical manual of mental disorders (dsm-5) score \>= 33; 4. assist score \>=11 for alcohol or \>=4 for any other substance 4. at risk for suboptimal hiv care engagement: at least one of the following: 1. engaged in hiv care for the first time within the past 6 months; 2. have an hiv rna viral load \>1,000 copies/ml within the past 6 months; 3. antiretroviral regimen was changed due to treatment failure within the past 6 months; 4. no-showed to an hiv primary care appointment within the past year. 5. willing to provide written informed consent. exclusion criteria: * 1. non-english speaking 2. unable to attend counseling sessions 3. unwilling to provide informed consent
the effect of fatima ana's hand on birth pain and duration

Conditions: Labor Pain; Labor Long

Summary: research question: does the anastatica hierochuntica have an effect on labor pain and duration? methods: this study was planned as a a double blind randomized controlled experimental study. the study was conducted with 60 pregnant women who were randomized between february 2019 and november 2020 at a university and private hospital located in anatolia, turkey.

complementary treatment methods during the birth process are supportive therapies. it is applied to meet the physical and psychological care needs, to help cope with pain during childbirth, to increase the quality of life of pregnant women. mind-body methods, alternative medical methods, biological-based treatment methods, manipulative and body-based methods, and energy therapy methods are used as complementary treatment methods in labor. the focus applied within the scope of mind-body methods is based on the principle of revealing the mental skill that improve bodily functions. one of the methods applied in this direction is anastatica hierochuntica. anastatika hierochuntica is a herbaceous plant that can live 1000-2000 years, with dry leaves resembling a fist-closed hand in which it stores its seeds. known as "fatma ana eli" or "meryem ana eli". this dry ball-shaped plant in the deserts of namibia comes alive in the rain and turns to green color by opening the folds. after the rain, the leaves of the plant, which stores some water to pass through a new drought period, close again and take a dry appearance. the plant anastatica hierochuntica is known to have a facilitating effect on labor and is frequently used for this purpose during labor. during childbirth, the anastatica hierochuntica plant is dropped into a bowl of water. it is believed that as the plant opens, labor will be easier, and the baby will flow like water. despite its frequent use, when the literature is examined, no studies hasve been found on the effect of anastatica hierochuntica on birth. for this reason, the study was conducted to evaluate the effect of anastatica hierochuntica on labor pain and duration.

Eligibility criteria:
inclusion criteria: * having a singleton pregnancy at 38-42 weeks, * pregnant women who had spontaneous labor, * pregnant women with a healthy fetus, * pregnant women without any complications that may cause dystocia during labor, * pregnant women who did not receive analgesia and anesthesia during the first phase of labor, * planned vaginal delivery, pregnant women who volunteered to participate in the research exclusion criteria: pregnant women with high-risk pregnancies, planned caesarean delivery, pregnant women with chronic diseases

Keywords: labor pain labor duration midwife anastatica hierochuntica